Once these challenges have been overcome, given the outstanding results of immunotherapy for other cancers (e.g. melanoma, lung cancer) and the expected efficacy of such treatment for HER2-positive disease, such therapies could revolutionize the course of HER2-positive breast cancer in the near future. This evidence concerns the gene ERBB2 and lung carcinoma.